EVFM - Evofem Biosciences, Inc.
| Previous Close | 3.8000 |
| Open | 3.7500 |
| Bid | 0.59 x 900 |
| Ask | 4.10 x 800 |
| Day's Range | 3.7500 - 4.0000 |
| 52 Week Range | 1.7920 - 12.5600 |
| Volume | 41,974 |
| Avg. Volume | 118,322 |
| Market Cap | 100.882M |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | Mar 21, 2019 - Mar 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.70 |
- ACCESSWIRE•11 days ago
Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive ...
- PR Newswire•14 days ago
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
The Company recently reported that its Phase 3 trial evaluating Amphora® for the prevention of pregnancy met its primary endpoint, and plans to resubmit the Amphora NDA in the second quarter of 2019.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
Q3 2018 Evofem Biosciences Inc Earnings Call
- Zacks•28 days ago
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
- Zacks•29 days ago
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
- Zacks•last month
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.
- ACCESSWIRE•last month
4 Stocks Providing Investor Opportunity Right Now
On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.
- Reuters•last month
Evofem's hormone-free birth control gel meets main goal in key study
Evofem Biosciences Inc said on Monday its hormone-free birth control gel met the main goal in a late-stage study. The company said it plans to resubmit the marketing application for Amphora in the second ...
- PR Newswire•last month
Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) ("Evofem" or the "Company") today announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint. AMPOWER assessed the efficacy, safety and subject satisfaction with Amphora in approximately 1,400 healthy women aged 18-35 years at 112 centers in the U.S. The primary endpoint of the study was the pregnancy rate over seven cycles of use (one cycle = 21-35 days) as assessed by the Kaplan-Meier statistical method.
- PR Newswire•2 months ago
Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018
Assuming positive results, Evofem expects to re-submit the Amphora New Drug Application in the first half of 2019 which, if approved by the FDA, would position the Company to commercialize Amphora in January 2020 as the first and only non-hormonal, on-demand prescription birth control method in the U.S. Evofem's management team will host one-on-one meetings with investors during the conference.
- PR Newswire•2 months ago
Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
Amphora is an investigational, first-in-class MVP-R designed to give a woman control over some of the most intimate issues of her life and health. This non-hormonal, non-systemic vaginal gel is being developed for woman-controlled birth control as well as prevention of certain sexually transmitted infections (STIs).
- PR Newswire•2 months ago
Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Management to Host Conference Call at 11:00 a.m. EST SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial ...
- PR Newswire•3 months ago
Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
- Currently 16.5M women in the U.S. are not using birth control and want to avoid pregnancy - Amphora®, a Multipurpose Vaginal pH Regulator product candidate, top-line Phase 3 data expected by YE 2018 ...
- PR Newswire•3 months ago
Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018
-- Conference Call Scheduled for 11:00 a.m. EST -- SAN DIEGO , Oct. 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed ...
- PR Newswire•3 months ago
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
SAN DIEGO, Oct. 9, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced details of two oral presentations of data related to their lead product, Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R) in late-stage development for prevention of pregnancy and prevention of urogenital transmission of chlamydia in women, at the 2018 American Society for Reproductive Medicine (ASRM) Annual Congress earlier today. "The data presented at ASRM, including patient satisfaction data from the AMP001 Phase 3 trial and important Phase 1 data on Amphora's ability to regulate vaginal pH, support the continuation of our robust clinical development initiatives," said Brandi Howard, PhD, Senior Vice President of Global Clinical Development Medical Affairs of Evofem Biosciences.
- PR Newswire•4 months ago
Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora®
-- On World Contraception Day, these U.S statistics support the continued need for new woman-controlled, non-hormonal birth control innovations. Ideally such methods would protect against pregnancy and also have other preventive indications (such as STI prevention), thus giving women better control over their sexual and reproductive health.
- PR Newswire•4 months ago
New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that new data from two clinical trials of Amphora®, its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, will be presented at the 2018 American Society for Reproductive Medicine (ASRM) Annual Congress taking place in Denver, Colorado on October 9, 2018. The two oral presentations will discuss new data from a previously completed Phase 3 clinical trial (AMP001) on Amphora's patient acceptability and assessment of genitourinary discomfort compared to nonoxynol-9 and outcomes of a Phase 1 clinical trial that evaluated Amphora's ability to alter vaginal pH, which underlies the potential of Evofem's MVP-R product candidates for birth control, for prevention of certain sexually transmitted infections (STIs), and to reduce the recurrence of bacterial vaginosis (BV).
- PR Newswire•4 months ago
Evofem Biosciences to Present at Upcoming Investor Conferences
Top-line data are expected by year-end 2018 from the second Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) for prevention of pregnancy. Assuming positive results, the Company plans to re-submit the Amphora New Drug Application (NDA) in the second quarter of 2019.
- Zacks•4 months ago
3 Small Biotech Stocks That Almost Doubled in Past Month
We take a look at three biotech stocks, prices of which have almost doubled in the past month.
- PR Newswire•5 months ago
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, believes that new data recently released by the Centers for Disease Control and Prevention (CDC) on the increasing rates of sexually transmitted diseases (STDs) in the United States support the continued need for and clinical development of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhea in women.
- PR Newswire•5 months ago
Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
Evofem's management team will also be available for one-on-one meetings with investors during the conference. Institutional investors who would like to attend the presentation or schedule a one-on-one meeting with the Company may register for the conference at http://www.rodmanevents.com. Evofem's lead product candidate, Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel, is being studied as a non-hormonal, on-demand vaginal contraceptive and for the prevention of certain sexually transmitted infections. The Company expects to report top-line data by year-end 2018 from its confirmatory Phase 3 clinical trial of Amphora for contraception.
- PR Newswire•5 months ago
Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit
SAN DIEGO, Aug. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem"), announced today that its Chief Medical Officer, Kelly Culwell, MD, will present at the #BlogHer18 Creators Summit, presented by SheKnows Media, on Wednesday, August 8, 2018 at 4:05 p.m. EDT in New York City. Dr. Culwell, aka Dr. Lady Doctor, will address an audience of over 2,000 health and lifestyle bloggers and social media influencers on the topic of unmet needs in women's reproductive healthcare including contraception, prevention of sexually transmitted infections like chlamydia, and bacterial vaginosis. In addition to this presentation, Dr. Culwell will launch a sexual and reproductive health platform, House Call with Dr. Lady Doctor, at the #BlogHer18 Creators Summit.
- PR Newswire•6 months ago
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018 Management to Host Conference Call at 11:00 a.m. ET SAN DIEGO , Aug. ...
- PR Newswire•6 months ago
Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018
-- Conference Call Scheduled for 11:00 a.m. EDT -- SAN DIEGO , July 19, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed ...
